Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Joo Hee Yi"'
Autor:
Susan Dent, Anthony Gonçalves, Joo-Hee Yi, Alexander Strasak, Pat LoRusso, Sandhya Girish, Priya Agarwal, Chunze Li, Marjorie C. Green
Publikováno v:
Cancer Research. 75:P4-15
Introduction Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate comprising trastuzumab, a stable linker, and the microtubule inhibitor DM1. In phase 3 studies of HER2-positive metastatic breast cancer (MBC), T-DM1 significantly increased p
Autor:
Meghna Samant, Dan Lu, Joo Hee Yi, Pierfranco Conte, Melody A. Cobleigh, Yuying Gao, Bei Wang, Ellie Guardino, Sandhya Girish, Mothaffar F. Rimawi, Jin Yan Jin
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate comprising the humanized monoclonal antibody trastuzumab linked to DM1, a highly potent cytotoxic agent. A population pharmacokinetic (PK) analysis was performed to estimate typica
Autor:
Amita Joshi, Yu-Waye Chu, Ola Saad, Sandhya Girish, David Loecke, Patricia LoRusso, Manish Gupta, Timothy J. Carrothers, Ted Shih, Joo-Hee Yi, Bei Wang
Publikováno v:
Clinical Pharmacology in Drug Development. 2:11-24
Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate in development for human epidermal growth factor receptor 2 (HER2)-positive cancer. Drugs in development are generally tested for their effects on QT interval, prolongation of which is assoc
Autor:
Kyu Hong, Caroline Amaya, Joo-Hee Yi, Jane Ruppel, Marija Milojic-Blair, Connie Mahood, Montserrat Carrasco-Triguero, Surinder Kaur
Publikováno v:
Bioanalysis. 4:2013-2026
Background: The standard safety evaluation of biotherapeutics includes assessment of immunogenicity. Anti-therapeutic antibodies (ATA) can be detected in serum using immunoassays with a bridging format. However, these assays can be subject to interfe
Autor:
E. Claire Dees, Bei Wang, Joo-Hee Yi, Javier Cortes, Sandhya Girish, Ted Shih, Yu-Waye Chu, Liang Fang, Howard A. Burris, Manish Gupta, Amita Joshi, Dan Lu
Publikováno v:
Current Drug Metabolism. 13:911-922
Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate comprised of trastuzumab and the cytotoxic agent DM1 (derivative of maytansine) linked by a stable linker N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC). T-DM1 targets
Autor:
Joo Hee Yi, Ian E. Krop, Howard A. Burris, Bei Wang, Dan Lu, Manish Gupta, S. N. Holden, Sandhya Girish, Barbara Tong, Yu Waye Chu, Patricia LoRusso, Amita Joshi, Charles L. Vogel, Ola Saad
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate comprising trastuzumab and DM1, a microtubule polymerization inhibitor, covalently bound via a stable thioether linker. To characterize the pharmacokinetics (PK) of T-DM1 in patien
Autor:
Joo-Hee Yi, Sandhya Girish, Jay Tibbitts, Mark X. Sliwkowski, Fred Jacobson, Howard A. Burris, Stuart G. Lutzker, Ian E. Krop, Wei Yu, Shanu Modi, S. N. Holden, Muralidhar Beeram, Suzanne F. Jones
Publikováno v:
Journal of Clinical Oncology. 28:2698-2704
Purpose Trastuzumab-DM1 (T-DM1) is an antibody-drug conjugate that uses trastuzumab to specifically deliver the maytansinoid antimicrotubule agent DM1 to HER2-positive cells. This first-in-human study of T-DM1 evaluated safety, pharmacokinetics, and
Autor:
Stephen Eppler, Stephen G. Ellis, Daniel L. Combs, Timothy D. Henry, Joo Hee Yi, Brian H. Annex, Edward R. McCluskey, John J. Lopez, Thomas F. Zioncheck
Publikováno v:
Clinical Pharmacology & Therapeutics. 72:20-32
Background The Vascular Endothelial Growth Factor (VEGF) in Ischemiafor Vascular Angiogenesis (VIVA) trial was a double-blind, placebo-controlled, phase II clinical trial designed to evaluate the safety, efficacy, and pharmacokinetics of combinedintr
Autor:
Kirsten Achilles Poon, Joo Hee Yi, Theresa Reynolds, Surinder Kaur, Joseph Beyer, Ola Saad, Noel Dybdal, Jay Tibbitts, Kelly Flagella, Sandhya Girish
Publikováno v:
Toxicology and applied pharmacology. 273(2)
Trastuzumab emtansine (T-DM1) is the first antibody-drug conjugate (ADC) approved for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. The therapeutic premise of ADCs is based on the hypothesis that tar
Autor:
Ola Saad, Corinna Lei, Joo-Hee Yi, Yanhong Li, Catherine Huang, Surinder Kaur, Randall C. Dere, Jakub Baudys
Publikováno v:
Bioanalysis. 5(9)
Background: Antibody–drug conjugates (ADCs) combine the characteristics of large-molecule biologics and small-molecule drugs and are heterogeneous mixtures that can biotransform in vivo, resulting in additional complexity. ADC bioanalytical strateg